Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

Oncologist

Volumn 16, Issue 4, 2011, Pages 388-403

  Ludwig, Heinz ^a   Beksac, Meral ^b   Bladé, Joan ^c   Cavenagh, Jamie ^d   Cavo, Michele ^e   Delforge, Michel ^f   Dimopoulos, Meletios ^g   Drach, Johannes ^h   Einsele, Hermann ⁱ   Facon, Thierry ^j   Goldschmidt, Hartmut ^k   Harousseau, Jean Luc ^l   Hess, Urs ^m   Kropff, Martin ⁿ   da Costa, Fernando Leal ^o   Louw, Vernon ^p   Magen Nativ, Hila ^q   Mendeleeva, Larisa ^r   Nahi, Hareth ^s   Plesner, Torben ^t   San Miguel, Jesús ^u   Sonneveld, Pieter ^v   Udvardy, Miklos ^w   Sondergeld, Pia ^x   Palumbo, Antonio ^y   more..

^a WILHELMINEN HOSPITAL   (Austria)

^b ANKARA UNIVERSITY   (Turkey)

^c HOSPITAL CLÍNIC   (Spain)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e Institute of Hematology and Clinical Oncology   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h University Clinic Vienna   (Austria)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l CENTRE RENÉ GAUDUCHEAU   (France)

^m Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

ⁿ UNIVERSITY OF MÜNSTER   (Germany)

^o INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^p UNIVERSITY OF THE FREE STATE   (South Africa)

^q RABIN MEDICAL CENTER   (Israel)

^r NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^s KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^t UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^u Centro de Investigacion del Cancer   (Spain)

^v ERASMUS MEDICAL CENTER   (Netherlands)

^w UNIVERSITY OF DEBRECEN   (Hungary)

^x Ammonite Systems Ltd   (United Kingdom)

^y UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PLACEBO; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHROMOSOME ABERRATION; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMORBIDITY; CONGRESSES AS TOPIC; DISEASE-FREE SURVIVAL; EUROPE; EVIDENCE-BASED PRACTICE; HUMANS; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 79955552589     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0386     Document Type: Article

References (83)

1. Ludwig H, Beksac M, Bladé J et al. Current multiple myeloma treatment strategies with novel agents: A European perspective. The Oncologist 2010;15:6-25.
2. van de Velde HJK, Liu X, Chen G et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399-1406.
3. Lahuerta JJ, Mateos MV, Martínez-López J et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-5782.
4. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-3146.
5. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28:2612-2624.
6. 2 and autologous transplantation (MEL200) in newly diagnosed multiple myeloma patients [abstract 3573]. Blood 2010;116:1471.
7. Morgan GJ, Davies FE, Gregory WM et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS [abstract 352]. Blood 2009;114:149.
8. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621-4629.
9. Moreau P, Attal M, Pégourié B et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood 2010 Nov 23 [Epub ahead of print].
10. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomized phase 3 study. Lancet 2010;376:2075-2085.
11. Sonneveld P, Schmidt-Wolf I, van der Holt B et al. HOVON-65/GMMGHD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract 40]. Blood 2010;116:23.
12. Paiva B, Vidriales MB, Montalbàn MA et al. Analysis of immunophenotypic response (IR) by multiparameter flow cytometry in 516 myeloma patients included in three consecutive Spanish trials [abstract 1910]. Blood 2010;116:796.
13. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood 2008;112:3107-3114.
14. Palumbo A, Delforge M, Catalano J et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients _65 years with newly diagnosed multiple myeloma (NDMM): Continuous use of lenalidomide vs fixed-duration regimens [abstract 622]. Blood 2010;116:273.
15. Harousseau JL, Palumbo A, Richardson PG et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010;116:3743-3750.
16. Palumbo A, Bringhen S, Cavalli M et al. Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: Updated follow-up and impact of prognostic factors [abstract 620]. Blood 2010;116:272.
17. Mateos MV, Oriol A, Martínez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 2010;11:934-941.
18. Gay F, Larocca A, Wijermans PW et al. Achievement of complete response is a strong prognostic factor in elderly newly diagnosed myeloma: Retrospective analysis of 1175 patients [abstract 1949]. Blood 2010;116:812.
19. Harousseau JL, Dimopoulos MA, Wang M et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738-1744.
20. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370:1209-1218.
21. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
22. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
23. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-2266.
24. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
25. Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010;28:3160-3166.
26. Waage A, Gimsing P, Fayers P et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-1412.
27. Einsele H, Liebisch P, Langer C et al. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa trial) [abstract 131]. Blood 2009;114: 59.
28. Harousseau JL, Avet-Loiseau H, Mary J et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib plus thalidomide-dexamethasone as induction prior to autologous transplantation in newly diagnosed myeloma [abstract 1097]. Haematologica 2010;95(suppl 2):451.
29. Moreau P, Facon T, Attal M et al. Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study [abstract 8014]. J Clin Oncol 2010;28(15 suppl):576s.
30. Lokhorst HM, van der Holt B, Zweegman S et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113-1120.
31. Rosiñol L, Cibeira MT, Mateos MV et al. A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: Superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib [abstract 307]. Blood 2010;116:139.
32. Moreau P, Hulin C, Marit G et al. Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 2010;24:1233-1235.
33. Kumar S, Flinn IW, Hari PN et al. Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: Encouraging results from the multicenter, randomized, phase 2 EVOLUTION study [abstract 127]. Blood 2009;114:57.
34. Kumar SK, Flinn I, Noga SJ et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter EVOLUTION study. Leukemia 2010;24:1350-1356.
35. Richardson PG, Weller E, Lonial S et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-686.
36. Richardson PG, Jagannath S, Jakubowiak AJ et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): Updated efficacy and safety data after >2 years of follow-up [abstract 3049]. Blood 2010;116: 1257.
37. Ludwig H, Viterbo L, Greil R et al. Phase II study of bortezomib, thalido-mide and dexamethasone/-cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): Safety and activity including evaluation of MRD [abstract 371]. Haematologica 2010;95(suppl 2):149-150.
38. van Rhee F, Szymonifka J, Anaissie E et al. Total Therapy 3 for multiple myeloma: Prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010;116: 1220-1227.
39. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28:4630-4634.
40. Goldschmidt H, Neben K, Bertsch U et al. Bortezomib-based induction therapy followed by autologous stem cell transplantation and maintenance therapy with bortezomib improves outcome in myeloma patients with fain 1q21 and t(4;14)-a subgroup analysis of the HOVON-65/GMMG-HD4 trial [abstract 305]. Blood 2010;116:138.
41. Mateos MV, Gutierrez NC, Paiva B et al. Clinical outcome according to both cytogenetic abnormalities (CA) detected by fluorescence in situ hybridization (FISH) and hyperdiploidy assessed by flow cytometry (FCM) in elderly newly diagnosed myeloma patients treated with a bortezomib-based combination [abstract 309]. Blood 2010;116:140.
42. Cavo M, Bringhen S, Terragna C et al. Bortezomib-based induction treatments improve outcomes of newly diagnosed multiple myeloma patients with high-risk cytogenetic abnormalities [abstract 781]. Blood 2010;116: 342.
43. Shaughnessy JD Jr, Zhan F, Burington BE et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-2284.
44. Decaux O, Lodé L, Magrangeas F et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008;26:4798-4805.
45. Broyl A, Hose D, Lokhorst H et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010;116:2543-2553.
46. Dickens NJ, Walker BA, Leone PE et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010;16:1856-1864.
47. Nair B, van Rhee F, Shaughnessy JD Jr et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010;115:4168-4173.
48. ClinicalTrials.gov. Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (HO95). Available at http://www.clinicaltrials.gov/ct2/show/NCT01208766, accessed March 10, 2011.
49. ClinicalTrials.gov. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (IFM/DFCI2009). Available at http://www.clinicaltrials.gov/ct2/show/NCT01208662?term_nct01208662&rank_1, accessed March 10, 2011.
50. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108:3289-3294.
51. Attal M, Lauwers V, Marit G et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Final analysis of the IFM 2005-02 [abstract 310]. Blood 2010;116:141.
52. Mellqvist UH, Westin J, Gimsing P et al. Improved response rate with bortezomib consolidation after high dose melphalan: First results of a Nordic Myeloma Study Group randomized phase III trial [abstract 530]. Blood 2009;114:221.
53. Ladetto M, Pagliano G, Ferrero S et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077-2084.
54. Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with lowdose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788-1793.
55. Cavo M, Perrone G, Buttignol S et al. Bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as induction and consolidation therapy before and after double autologous transplantation in newly diagnosed multiple myeloma: Results from a randomized phase 3 study [abstract 42]. Blood 2010;116:25.
56. Terragna C, Zamagni E, Petrucci MT et al. Molecular remission after bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: Results of a qualitative and quantitative analysis [abstract 861]. Blood 2010;116:376.
57. Barlogie B, Attal M, Crowley J et al. Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the Intergroupe Francophone du Myélome, Southwest Oncology Group, and University of Arkansas for medical sciences. J Clin Oncol 2010;28: 1209-1214.
58. Stewart AK, Trudel S, Bahlis NJ et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 trial [abstract 39]. Blood 2010;116:23.
59. McCarthy PL, Owzar K, Anderson KC et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract 37]. Blood 2010;116:21.
60. Beksac M, Haznedar R, Firatli-Tuglular T et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011;86:16-22.
61. Palumbo A. Balancing act for elderly myeloma. Blood 2010;116:1390-1391.
62. Waage A, Palumbo A, Hulin C et al. MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta analysis of survival of 1682 individual patient data from 6 randomized clinical trials [abstract 567]. Haematologica 2010;95(suppl 2):235.
63. Ludwig H, Hajek R, Tóthov, E et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113:3435-3442.
64. Palumbo A, Falco P, Benevolo G et al. A multicenter, open label study of oral lenalidomide and prednisone (RP) followed by oral lenalidomide melphalan and prednisone (MPR) and oral lenalidomide maintenance in newly diagnosed elderly multiple myeloma patients [abstract 1940]. Blood 2010; 116:808.
65. Kropff M, Richardson PG, Schlag R et al. Similar benefit in patients aged ≥75 vs <75 y with VMP in frontline MM and bortezomib in relapsed MM [abstract 084]. Clin Lymphoma Myeloma 2009;9(1 suppl):512.
66. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-4753.
67. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 2010;28: 5101-5109.
68. Moreau P, Pylypenko HV, Grosicki S et al. A phase 3 prospective randomized International study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma [abstract 312]. Blood 2010;116:142.
69. Jacobus S, Callander N, Siegel D et al. Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide/high-dose dexamethasone (RD) versus lenalidomide/lowdose dexamethasone (Rd) [abstract 370]. Haematologica 2010;95(suppl 2): 149.
70. Niesvizky R, Richardson PG, Rajkumar SV et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143:46-53.
71. Lokhorst H, Einsele H, Vesole D et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stemcell transplantation for multiple myeloma. J Clin Oncol 2010;28:4521-4530.
72. Wang M, Dimopoulos MA, Chen C et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445-4451.
73. Dimopoulos MA, Kastritis E, Christoulas D et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: Prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769-1778.
74. Madan S, Lacy M, Dispenzieri A et al. Efficacy of retreatment with immuno-modulatory compounds in patients receiving initial therapy for newly diagnosed multiple myeloma [abstract 1964]. Blood 2010;116:820.
75. Petrucci T, Blau I, Corradini P et al. Efficacy and safety of retreatment with bortezomib in patients with multiple myeloma: Interim results from RETRIEVE, a prospective international phase 2 study [abstract 377]. Haematologica 2010;95(suppl 2):152.
76. Kumar S, Blade J, Crowley J et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study [abstract 2878]. Blood 2009;114: 1123.
77. Dimopoulos MA, Richardson PG, Schlag R et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27:6086-6093.
78. Ludwig H, Adam Z, Hajek R et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 2010;28:4635-4641.
79. Roussou M, Kastritis E, Christoulas D et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395-1397.
80. Dimopoulos M, Alegre A, Stadtmauer EA et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010;116:3807-3814.
81. Delforge M, Bladé J, Dimopoulos MA et al. Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues. Lancet Oncol 2010;11:1086-1095.
82. Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
83. Mateos MV, López-Corral L, HernàndezM et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: A phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs so treatment [abstract 1935]. Blood 2010;116:805.